P a t r i c k M e y e r
and J a c q u e s P h i l i p p e 2 
Senior Resident; 2. Vice Dean of Research, and Chief, Division of Endocrinology, Diabetes and Nutrition, University Hospitals Geneva
The prevalence of diabetes in Europe has been dramatically increasing since the early 1990s. It is estimated that in 2007, 53 million people had diabetes in Europe. Quantitatively, Russia and Germany have the highest number of people with diabetes, with a combined figure of about 17 million. When the age group of 22-79 years is considered, in some
European countries -such as Ukraine, Germany and Russia -as much as 10% of the population is affected by diabetes. 1 The obvious consequence of the epidemic of type 2 diabetes is an increase in both macro-and micro-angiopathic complications. In 2000, the number of excess deaths due to diabetes was estimated to be 2.9 million worldwide (5.2% of all deaths). The excess death rate in particular concerns the age group from 30 to 75 years. 2 
Why Do We Need Good Metabolic Control?
There are a number of reasons to achieve good metabolic control.
Intervention studies such as the Diabetes Control and Complications Trial
(DCCT), 3 the UK Prospective Diabetes Study (UKPDS) 4 and Steno II 5 (carried out by the Steno Diabetes Centre, Norway) have shown the importance of metabolic control in the prevention of diabetic complications. In addition, the large number of people with diabetes incurs enormous health costs if prevention and control are not better achieved. However, long-term control is particularly difficult to achieve because diabetes is a disease in which compliance with treatment and lifestyle is imperative to achieve success. Furthermore, the disease evolves with a progressive loss of β-cell function. Also, the available medications have limitations in terms of efficacy and side effects.
Treatment of Type 2 Diabetes -The New Guidelines
The standard approach to the management of type 2 diabetes is well accepted and simple in theory. At the time of diagnosis, diet, exercise and monotherapy with metformin are widely accepted. When this therapy becomes insufficient, combination therapy with two or three oral agents is started. When necessary, insulin is later added to other therapies, and finally multiple injections of insulin have to be started for a significant percentage of diabetic patients later in the evolution of the disease. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) established recommendations for the treatment of type 2 diabetes in 2006. 6 Once the diagnosis of diabetes is established, these recommendations propose starting active lifestyle interventions plus metformin.
When these initial measures fail to maintain a glycated haemoglobin (HbA 1c ) level under 7%, the recommendations are to add insulin, which is the most effective (at least acutely), a sulfonylurea (the least expensive) or a glitazone, which has the advantage of not causing hypoglycaemia. When the second step is unable to maintain the HbA 1c level at less than 7%, additional combination therapy is required until intensive insulin treatment is started. Of note, metformin is maintained throughout these different steps. The different antidiabetic medications have similar efficacy, at least during the first year of treatment, and lead to decreases in HbA 1c of 1-2%. However, each has advantages and disadvantages (see Figure 1) .
Lifestyle changes are low-cost and have many health benefits.
Unfortunately, they are usually effective only in the short term because compliance is difficult to maintain. Metformin is weight-neutral and inexpensive; however, it has gastrointestinal side effects with rare episodes of lactic acidosis. Sulfonylureas are inexpensive too, but they cause weight gain and hypoglycaemia. Glitazones markedly improve insulin resistance and triglycerides, but they are associated with fluid retention, weight gain, macular oedema and osteoporosis, and they are also expensive. Finally, insulin has no dose limits, is inexpensive and leads to an improved lipid profile; however, it requires injections and can cause hypoglycaemia and weight gain. Additional treatments such as glinideswhich increase insulin secretion similar to sulfonylureas, but with a shorter duration of action -and alpha glucosidase inhibitors -which delay intestinal carbohydrate absorption -may be helpful in the treatment of diabetes, but usually have slightly decreased efficacy compared with the alternative treatments.
New treatments available on the market include glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, which improve glucose-dependent insulin secretion and lead to weight loss for the GLP-1 analogues. 7 These treatments are based on the observation made several decades ago that enteral nutrition provides a more potent insulinotropic stimulus compared with a comparable glucose intravenous load, leading to the incretin concept. The two incretins identified in the last decade are GLP-1 and glucose-dependent insulinotropic peptide (GIP). 7 The first GLP-1 analogue to enter the market is exenatide. Exenatide is a subcutaneously injected incretin mimetic. It is indicated as adjunctive therapy to improve glycaemic control in patients who are already receiving therapy with metformin, a sulfonylurea or both, and who have suboptimal glycaemic control. Exenatide improves glucose homeostasis by mimicking
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Jacques Philippe is Vice Dean of Research and Chief of the Division of Endocrinology, Diabetes and Nutrition at the University Hospitals Geneva. He is also head of a research laboratory at the Geneva Medical School, where his main research interests are the study of genes involved in insulin and glucagon regulation, the genetic causes of noninsulin-dependent diabetes and the autotransplantation of pancreatic islet tissue following pancreatectomy. Dr Philippe has written numerous articles and scientific reviews for many leading international scientific journals. values of 0.8-1%. There was also dose-dependent progressive weight loss compared with placebo. Nausea was the most commonly reported adverse event in the exenatide groups (about 40%). Other adverse events occurring in more than 10% of patients receiving exenatide were hypoglycaemia, diarrhoea and vomiting. Of interest, the reduction in HbA 1c was sustained over two years, as was the mean weight loss of about 5kg. 8 A multinational, randomised, open-label study compared the effects of exenatide with those of insulin glargine in patients with type 2 diabetes who did not achieve adequate glycaemic control with a combination of metformin and a sulfonylurea at maximally effective doses. At the end of 26 weeks of therapy, HbA 1c was decreased by 1.1% in both groups; however, mean bodyweight decreased by 2.3kg in the exenatide group and increased by 1.8kg in the insulin glargine group. Nausea was the most common adverse event in the exenatide group compared with the insulin glargine group, while the overall rate of hypoglycaemia was similar in the two groups. 9 Anti-exenatide antibodies are detected in about 40% of patients treated in clinical trials. The majority of these patients have low antibody titres and no effects on glycaemic control. As exenatide delays gastric emptying, it may also affect the rapidity of absorption of multiple drugs. 8 Exenatide Endocannabinoid receptor antagonists such as rimonabant are also helpful in the treatment of type 2 diabetes due to their favourable effects on weight through inhibition of food intake and increased lipolysis. 10 The endocannabinoid system, which is functional in multiple organs including the brain, the adipose tissue, the liver and the pancreatic β cells, is overactive in obesity, probably secondary to a high-fat diet and increased food intake. This creates a vicious cycle, with increased lipogenesis in adipocytes and the liver leading to abdominal obesity and liver steatosis and, potentially, to excessive insulin secretion. 11 At insulin initiation, the average patient had five years with glycated haemoglobin (HbA1c) >8% and 10 years with HbA1c >7%. Adapted from Brown et al., 2004. 17 Developments level of less than 6.5% was about 3% with conventional therapy and only 15% with intensive therapy. 5 Similar results were observed in Switzerland in five university centres. Indeed, an observational study reported that only 13% of patients treated in the diabetes clinics in these university hospitals had HbA 1c levels of less than 6.5%. 15 
Why Do We Have So Much Difficulty Controlling Diabetes?
The progressive loss of β-cell function that is already ongoing at diagnosis of diabetes, 12 followed by the subsequent lifestyle changes even when patients are intensively educated (see Figure 2) , are not always totally effective, as suggested by the Steno II study. 5 Also, many of the treatment options in diabetes lead to increases in weight, which may have detrimental effects in the long term. Doctors should also react much earlier in trying to improve diabetes control in their patients. An elegant study showed that at insulin initiation, the average diabetic patient has spent about five years with an HbA 1c level of more than 8% and about 10 years with a level of more than 7%. 17 Multiple difficulties exist in adapting treatment, particularly starting insulin (see Table 1 ). Physicians always hope that lifestyle will eventually improve diabetes control; however, patients are often reluctant to take more medications. For insulin, the need for education and the time spent demonstrating the use of specific materials and how to perform injections are major limiting factors. The requirements for more rigorous diet obligations and more frequent blood glucose monitoring, the appearance of more severe and more frequent hypoglycaemia, the problem of weight gain, the risk of more errors and a bad social representation of disease severity are all barriers to starting insulin. This requires good communication skills and time to convince patients that it will be beneficial for them.
Although increases in medication or in prescribing insulin may be translated as an increase in disease severity, increased organisation and more risks, this will eventually pay off with a decreased complication rate and an increased lifespan for the patient.
In conclusion, the major difficulties in controlling diabetes are mainly due to psychosocial reasons because of the daily requirements for selfmanagement and compliance, the evolution of the disease and the limitations of the available medications. Thus, new concepts may not mean improved management of diabetes. Improved management of diabetes will require more efforts from both the patient and the doctor.
These efforts involve mandatory lifestyle adaptations and increased physician vigour to adapt treatment. However, the development of new treatments may offer major advantages in terms of diabetes control because we need medications that lead to weight loss and improved glucose and lipid profiles, with good tolerance, limited side effects and, eventually, improved life quality and expectancy. I
